Akèy › Kansè Poumon ki pa ti selil › Nevada › Reno
Etid klinik pou Kansè Poumon ki pa ti selil nan Reno, NV
16 etid pou Kansè Poumon ki pa ti selil ap chèche patisipan nan sit nan ak bò kote Reno (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Ap rekriteFaz 3
- Gene Upshaw Memorial Tahoe Forest Cancer Center, Truckee · 24 mi lwen
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
Ap rekriteFaz 3
- Renown Regional Medical Center-Renown Health Medical Oncology ( Site 3207), Reno
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Ap rekriteFaz 3
- Renown Health Medical Oncology, Reno
- Renown Office of Clinical Research, Reno
- Renown Regional Medical Center, Reno
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Ap rekriteFaz 3
- Renown Regional Medical Center-Renown Health Medical Oncology ( Site 0037), Reno
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
Ap rekriteFaz 3
- Renown Regional Medical Center-Renown Health Medical Oncology ( Site 0134), Reno
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
Ap rekriteFaz 3
- Research Site, Reno
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
Ap rekriteFaz 3
- Renown Regional Medical Center, Reno
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 2
- Renown Regional Medical Center /ID# 273535, Reno
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Ap rekriteFaz 2/3
- Renown Regional Medical Center, Reno
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
Ap rekriteFaz 3
- Cancer Care Specialists, Reno
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
Ap rekriteFaz 3
- Renown Regional Medical Center, Reno
A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 3
- Cancer Care Specialists, Reno
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Ap rekriteFaz 3
- Cancer Care Specialists, Reno
Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer
Ap rekriteFaz 2
- Tahoe Forest Cancer Center, Truckee · 24 mi lwen
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Ap rekriteFaz 2/3
- Gene Upshaw Memorial Tahoe Forest Cancer Center, Truckee · 24 mi lwen
GEMINI-NSCLC: NSCLC Biomarker Study
Ap rekriteEtid obsèvasyon
- Cancer Care Specialists Reno, Reno
Etid Kansè Poumon ki pa ti selil nan lòt vil
- Houston, TX145 etid
- New York City, NY120 etid
- Arlington, VA104 etid
- Nashville, TN97 etid
- Boston, MA90 etid
- Los Angeles, CA87 etid
- St. Louis, MO73 etid
- Chicago, IL61 etid
- Baltimore, MD60 etid
- San Antonio, TX59 etid
- Columbus, OH56 etid
- Washington, DC55 etid
Lòt etid nan Reno
- Kansè nan tete13 etid
- Kansè poumon9 etid
- Degeneresans makile8 etid
- Atrofi Jeyografik8 etid
- Kansè ovè7 etid
- Kansè (tout kalite)7 etid
- Kansè kolorektal5 etid
- Leksemi mieloïd egi5 etid
- Kansè Metastatik5 etid
- Kansè pankreyas5 etid
- Kansè kolon5 etid
- Kansè rektal4 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.